Oxford Biomedica plcOXB.L
What Oxford Biomedica plc does.
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems; InAAVate, a proprietary plug and play' dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | £142.8M | £140.0M | £89.5M | £128.8M | £168.7M |
| Net income | £19.0M | -£39.2M | -£157.5M | -£43.2M | -£30.1M |
| Free cash flow | £16.0M | -£28.9M | -£38.3M | -£58.2M | -£4.3M |
More on OXB.L.
- Oxford Biomedica plc summary
- Oxford Biomedica plc financial statements
- Oxford Biomedica plc key metrics
- Oxford Biomedica plc health scores
- Oxford Biomedica plc valuation
- Oxford Biomedica plc dividends
- Oxford Biomedica plc peers
- Oxford Biomedica plc annual reports
Figures from Oxford Biomedica plc's annual reports (ESEF, via filings.xbrl.org) and Yahoo Finance, standardised automatically; prices are end-of-day closes. Not financial advice.